Kristine Rinn - Concepedia

Concepedia

Author

Kristine Rinn

University of Washington

Also Known As

K Rinn, K. Rinn, Kristine J Rinn, Kristine J. Rinn, Kristine Rinn

32

Publications

1.3K

Citations

12

H-Index

30

Concepts

All Affiliations

University of Washington Seattle Cancer Care Alliance University of Washington Medical Center Swedish Medical Center SWOG Cancer Research Network

KR

About

Kristine Rinn is an author at University of Washington specializing in medicine, breast cancer, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	517
2	Immunology	4	4	300
3	Health Sciences	2	2	154
4	Allergy	2	2	130
5	Pathology	2	2	75

Kristine Rinn

×

13

Publications

1.3K

Citations

12

H-Index

	Year	Citations
Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines Mary L. Disis, Theodore A. Gooley, Kristine Rinn, Journal of Clinical Oncology	2002	424
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Mary L. Disis, Keith L. Knutson, Kathy Schiffman, Breast Cancer Research and Treatment Her-2/neu Oncogenic ProteinBreast OncologyOncogenic AgentImmunologyBreast Cancer	2000	158
Use of Serial FDG PET to Measure the Response of Bone-Dominant Breast Cancer to Therapy S. E. Stafford, Julie R. Gralow, Erin K. Schubert, Academic Radiology Breast OncologyBone ImagingMedicineSerial Fdg PetBone-dominant Breast Cancer	2002	143
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer G. Thomas Budd, William E. Barlow, Halle C. F. Moore, Journal of Clinical Oncology	2014	119
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. M L Disis, K Schiffman, Ted Gooley, PubMed Adaptive Immune SystemCellular ImmunologyImmunologyImmunoeditingAntigen Processing	2000	113
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers Mary L. Disis, Kristine Rinn, Keith L. Knutson, Blood	2002	84
A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu Prema P. Peethambaram, Michelle Melisko, Kristine Rinn, Clinical Cancer Research	2009	84
[Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow David A. Mankoff, Lisa K. Dunnwald, Julie R. Gralow, Nuclear Medicine and Biology Advanced Breast CancerBreast OncologyMedicinePathologyBreast Cancer	2002	63
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report Fengting Yan, Kristine Rinn, Jonathon A. Kullnat, Journal of the National Comprehensive Cancer Network	2022	18
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients Kathy Schiffman, Kristine Rinn, Mary L. Disis Breast Cancer Research and Treatment Tumor ImmunologyBreast OncologyAllergyCancer ImmunosurveillanceMedicine	2002	17

Page 1